Skip to Content

Generic Soolantra Availability

Last updated on Sep 8, 2021.

Soolantra is a brand name of ivermectin topical, approved by the FDA in the following formulation(s):

SOOLANTRA (ivermectin - cream;topical)

Has a generic version of Soolantra been approved?

A generic version of Soolantra has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Soolantra and have been approved by the FDA:

ivermectin cream;topical

  • Manufacturer: TEVA PHARMS USA
    Approval date: September 13, 2019
    Strength(s): 1% [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Soolantra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Treatment of papulopustular rosacea with ivermectin
    Patent 10,206,939
    Issued: February 19, 2019
    Assignee(s): Galderma S.A.

    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

    Patent expiration dates:

    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Patent 11,033,565

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 7,550,440
    Issued: June 23, 2009
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,080,530
    Issued: December 20, 2011
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,093,219
    Issued: January 10, 2012
    Inventor(s): Manetta; Vincent & Watkins; Gary R.
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,415,311
    Issued: April 9, 2013
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,470,788
    Issued: June 25, 2013
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent 8,815,816
    Issued: August 26, 2014
    Assignee(s): Galderma S.A.

    Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

    Patent expiration dates:

    • April 22, 2024
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
      ✓ 
      Drug product
  • Treatment of papulopustular rosacea with ivermectin
    Patent 9,089,587
    Issued: July 28, 2015
    Assignee(s): Galderma S.A.

    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

    Patent expiration dates:

    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Treatment of inflammatory lesions of rosacea with ivermectin
    Patent 9,233,117
    Issued: January 12, 2016
    Assignee(s): Galderma S. A.

    Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.

    Patent expiration dates:

    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Treatment of papulopustular rosacea with ivermectin
    Patent 9,233,118
    Issued: January 12, 2016
    Assignee(s): Galderma S.A.

    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

    Patent expiration dates:

    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
  • Treatment of papulopustular rosacea with ivermectin
    Patent 9,782,425
    Issued: October 10, 2017
    Assignee(s): Galderma S.A.

    Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

    Patent expiration dates:

    • March 13, 2034
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.